Precigen stock hits 52-week high at 7.74 USD
- Investing.com
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Precigen Inc (PGEN)
Precigen Inc stock price live, this page displays NASDAQ PGEN stock exchange data. View the PGEN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Precigen Inc real time stock price chart below.
What Is the Precigen Inc Stock Price Today?
The Precigen Inc stock price today is 7.780.
What Is the Stock Symbol for Precigen Inc?
The stock ticker symbol for Precigen Inc is PGEN.
Is PGEN the Same as $PGEN?
$PGEN is a common way to refer to the Precigen Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Precigen Inc Trade On?
Precigen Inc is listed and trades on the NASDAQ stock exchange.
Is Precigen Inc a Good Stock to Buy?
Determining whether Precigen Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Precigen Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PGEN quote. (ISIN: US74017N1054)
What Is the Precigen Inc Stock Price Today?
The Precigen Inc stock price today is 7.780.
What Is the Stock Symbol for Precigen Inc?
The stock ticker symbol for Precigen Inc is PGEN.
Is PGEN the Same as $PGEN?
$PGEN is a common way to refer to the Precigen Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Precigen Inc Trade On?
Precigen Inc is listed and trades on the NASDAQ stock exchange.
Is Precigen Inc a Good Stock to Buy?
Determining whether Precigen Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Precigen Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PGEN quote. (ISIN: US74017N1054)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.695
8.039
52 wk Range
2.990
8.039
Trading near 52-week High
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.6958.039
52 wk Range
2.9908.039
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PGEN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
14.500
Upside
+86.38%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
Precigen stock hits 52-week high at 7.33 USD- Investing.com
Intrexon Corpn receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Precigen stock hits 52-week high at 7.74 USD
- Investing.com
Precigen COO Rutul Shah sells $375,000 in shares- Investing.com
Precigen CCO Phil Tennant sells $593,745 in stock- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Analyst Ratings
2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 14.500
(+86.38% Upside)
Precigen Inc SWOT Analysis
Market Sentiment | Analyst targets range from $8.00 to $8.50, reflecting optimism about Precigen's growth potential and the transformative impact of PAPZIMEOS on the RRP treatment landscape |
Pipeline Potential | Uncover Precigen's diverse pipeline, featuring promising candidates like PRGN-2009 and PRGN-3006, showcasing the company's innovative gene therapy platform |
Financial Trajectory | Delve into Precigen's financial outlook, including its $98 million cash runway and the impact of PAPZIMEOS's $460,000 price point on future profitability |
RRP Breakthrough | Explore Precigen's PAPZIMEOS, the first FDA-approved therapy for Recurrent Respiratory Papillomatosis, offering hope to patients and potential market dominance |
Precigen Inc Earnings Call Summary for Q2/2026
- Precigen posted Q2 EPS of $0.05 vs. consensus loss of $0.01; revenue hit $54.98M, nearly double the $27.83M estimate, driven by PAPZIMEOS.
- PAPZIMEOS generated $53.1M (96.4% of revenue), with over 200 patients dosed; permanent J-code and payer coverage accelerated hospital adoption.
- Company swung to $20.1M net income with 94.7% gross margin; expects margins to normalize to high-80s/low-90s range as pre-launch inventory depletes.
- Management forecasts cash flow breakeven by end-2026; Q3 growth expected to continue but at moderating pace as launch matures and account base expands.
- Stock surged 12.56% after-hours to $7.35, surpassing 52-week high; analysts maintain buy ratings with $11-$14 price targets on blockbuster potential.
Last Updated: 08/04/2026, 05:23 PM
Read Full TranscriptEarnings
Latest Release
Aug 04, 2026
EPS / Forecast
0.05 / -0.01
Revenue / Forecast
54.98M / 27.83M
Compare PGEN to Peers and Sector
Metrics to compare | PGEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPGENPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.3x | −2.0x | −0.4x | |
PEG Ratio | 0.06 | −0.09 | 0.00 | |
Price / Book | 63.9x | 4.0x | 2.6x | |
Price / LTM Sales | 32.5x | 4.4x | 3.0x | |
Upside (Analyst Target) | 86.4% | 324.4% | 54.5% | |
Fair Value Upside | Unlock | 15.3% | 7.0% | Unlock |
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Precigen (PGEN) Stock Price Today?
The Precigen stock price today is 7.780 USD.
What Stock Exchange Does Precigen Trade On?
Precigen is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Precigen?
The stock symbol for Precigen is "PGEN."
What Is the Precigen Market Cap?
As of today, Precigen market cap is 2.820B USD.
What Is Precigen's Earnings Per Share (TTM)?
The Precigen EPS (TTM) is -0.984.
When Is the Next Precigen Earnings Date?
Precigen will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is PGEN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Precigen Stock Split?
Precigen has split 0 times.
How Many Employees Does Precigen Have?
Precigen has 160 employees.
What is the current trading status of Precigen (PGEN)?
As of Sep 19, 2026, Precigen (PGEN) is trading at a price of 7.780 USD, with a previous close of 7.780 USD. The stock has fluctuated within a day range of 7.695 USD to 8.039 USD, while its 52-week range spans from 2.990 USD to 8.039 USD.
What Is Precigen (PGEN) Price Target According to Analysts?
The average 12-month price target for Precigen is 14.500 USD, with a high estimate of 18 USD and a low estimate of 11 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +86.38% Upside potential.
What Is the PGEN Premarket Price?
PGEN's last pre-market stock price is 8.010 USD. The pre-market share volume is 12,780.000, and the stock has decreased by 0.140, or 1.780%.
What Is the PGEN After Hours Price?
PGEN's last after hours stock price is 7.760 USD, the stock has decreased by -0.020, or -0.260%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.